Valeo Financial Advisors LLC Purchases New Position in Evotec AG $EVO

Valeo Financial Advisors LLC acquired a new stake in shares of Evotec AG (NASDAQ:EVO) in the second quarter, HoldingsChannel.com reports. The firm acquired 10,241 shares of the company’s stock, valued at approximately $43,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE increased its position in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares in the last quarter. UMB Bank n.a. bought a new stake in Evotec during the second quarter worth about $56,000. ABC Arbitrage SA bought a new stake in Evotec during the first quarter worth about $260,000. Finally, DCF Advisers LLC grew its stake in Evotec by 227.0% during the first quarter. DCF Advisers LLC now owns 751,579 shares of the company’s stock worth $2,510,000 after buying an additional 521,708 shares during the last quarter. 5.81% of the stock is owned by institutional investors.

Evotec Stock Down 1.8%

NASDAQ EVO opened at $3.87 on Friday. The stock has a fifty day moving average of $3.66 and a 200-day moving average of $3.84. Evotec AG has a 52 week low of $2.84 and a 52 week high of $5.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.58 and a quick ratio of 1.49.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Evotec in a report on Wednesday. HC Wainwright cut their price objective on Evotec from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Evotec in a research note on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evotec presently has an average rating of “Hold” and a consensus price target of $7.00.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.